Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Clinical trial NCT03267186 · COMPLETED

Trial details

NCT number: NCT03267186
Sponsor: Andrew Rezvani
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Biphenotypic Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hematopoietic Cell Transplantation Recipient

Start date: 2017-09-12
Primary completion: 2021-04-30
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.